Antitumor efficacy of extracellular complexes with gadolinium in Binary Radiotherapy.

In this report the efficacy of extracellular pharmaceutical Gd-DTPA in Binary Radiotherapy was studied. The study was carried out in mice bearing transplantable adenocarcinoma Ca755 using X-ray based contrast enhanced radiotherapy as a practical implementation of Binary Radiotherapy. It was shown that intravenous administration of 0.3 ml of 0.5 M water solution of Gd-DTPA followed by X-irradiation at a dose of 10 Gy provides T/C%=10±3% and leads to complete tumor regression in 25% of mice.

[Increase of X-ray radiotherapy antineoplastic efficacy by use of a gadolinium containing pharmaceutical].

The influence of the gadolinium-containing drug Dipentast (0.5 M water solution of sodium gadopentetate) on the antineoplastic efficacy of X-ray radiotherapy has been studied. Dipentast possesses neither intrinsic antitumor effect, nor tumor-seeking capability. Mice C57Bl/6 with transplanted adenocarcinoma Ca755 were used in the study. The mice were irradiated with an X-ray machine with an anode voltage of 200 kV. The absorbed dose in the tumor after irradiation was 10 Gy for both experimental and control groups. The mice in the experimental group were treated with a single intraperitoneal injection of 0.3 ml of Dipentast. The observation of the tumour growth rate has shown that intraperitoneal administration of Dipentast prior to X-ray irradiation results in a significant tumour growth delay (12 ± 1 days for the experimental group versus 2 ± 1 in the control group), increasing the median life span from 36 ± 1 days in the control group to 43 ± 1 days in the experimental group, and leads to complete disappearance of the tumour in 25 ± 1% of the animals in the experimental group, while in the control group, no tumour regression was observed.

[The diagnosis of epilepsy by using blood analysis for the content of autoantibodies to glutamate neuroreceptors]. / Diagnostika épilepsii s pomoshch'iu analiza krovi na soderzhanie autoantitel k neiroretseptoram glutamata.

The glutamate receptor autoantibody level was studied in blood of 170 epileptic patients as well as of 114 control donors (64 patients with nonepileptic cerebral pathology and 50 healthy individuals). The elevation of autoantibodies level (higher than 140%) was observed in 63.5% of patients with paroxysmal epileptic disturbances. This elevation was observed more frequently in the initial period of the disease as well as in generalized (convulsive or nonconvulsive) fits irrespective of disease etiology. Combined application of the test with EEG method permitted to confirm the epileptic nature of the disease in 83.5% of cases. The results of repeated analysis of glutamate receptor autoantibody level in blood proved to be a significant criterion of the effectiveness of anticonvulsive therapy. It also allowed to predict the development of posttraumatic epilepsy in individuals with craniocerebral trauma in the past.